This is a tough debunk/fact
. It’s experimental & recent trials less convincing. Vaccines prevent & far superior @<5% the cost. The issue w post-infection, mutation-inducing antiviral is people will obtain it outside of clinical supervision/black market & use like antibiotics …https://twitter.com/estherswchan/status/1465832180282658817 …
-
Show this thread
-
When you don’t finish a full course at an effective dosage, esp if immunocompromised, it could potentially make dealing with variants worse. Black market remdesivir/antivirals a huge industry—surges w flu outbreaks, with MERS in 2012 & Covid-19. So less a matter of if but when …
1 reply 0 retweets 1 likeShow this thread -
At this point, the facts are: molnupiravir is experimental, may accelerate mutations if not administered properly, barely passed the first committee vote, & involves a ~$3.5 billion govt contract. Disinfo-wise, it’s near-impossible to debunk most for/against claims w certainty.
1 reply 2 retweets 1 likeShow this thread -
This is the technical area of comms where general fact-checking/debunking might benefit from restraining until a clear signal is given; we have scientific research that informs multiple levels of experts re: regulation & approval
1 reply 0 retweets 1 likeShow this thread -
Replying to @d1gi
That “fact check” is incorrect. It’s conflating real issues with obviously wrong things. It doesn’t even have its own facts correct.
2 replies 0 retweets 2 likes
The “correction” making strong claims even Merck isn’t making. People really need to hold off with these things unless they have the right team and expertise.
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.